Endocrine Gut Tumor

Answer: C.

Although, some studies have suggested that chemotherapy has marginal benefit (tumor stabilization or mild shrinkage) in patients with metastatic disease, survival does not appear to be significantly impacted in patients with NET’s. Leukocyte interferon has been used with varying success in this group of patients. It is not considered first line treatment due to it’s limited benefit as a single agent and drug toxicity (A). OLT has been utilized with marginal success in patients with metastatic disease and is not considered standard therapy in this patient population (B). Selected patients, for example those with limited metastatic disease, those with symptoms refractory to medical therapy may benefit from aggressive debulking procedures (D).

Category: